Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eon Generic Wellbutrin SR Injunction Vacated

This article was originally published in The Pink Sheet Daily

Executive Summary

Eon no longer has the threat of a preliminary injunction hanging over its Wellbutrin SR generic (bupropion sustained-release)

You may also be interested in...



Impax/Teva Launch Wellbutrin SR Generic As Andrx Relinquishes Exclusivity

The 150 mg Impax/Teva product is following Eon's and Watson's 100 mg generics to the market. Andrx will receive a share of the profits.

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel